A gene therapy from Regeneron, a pancreatic cancer medicine from Revolution Medicines and a porphyria drug from Disc Medicine ...

Shares of Praxis Precision Medicines more than tripled Thursday, peaking at $200 apiece, after the company disclosed positive ...

However, if pharma manufacturers aren’t using RWD in a strategic way, they’ll miss out on its full potential. And with that, ...

Nilo Therapeutics, which launched Wednesday, is trying to develop drugs that regulate inflammation and the immune system by ...

The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called ...

Study results published in The New England Journal of Medicine show the therapy significantly improved hearing in nearly a ...

Backed by GV and Arch Venture Partners, Pelage Pharmaceuticals is advancing a first-of-its-kind topical gel designed to ...

Results presented at the European Society for Medical Oncology meeting could help separate Roche’s medicine from similar ...

The German biotech banked one of the larger funding rounds this year to support an ovarian and non-small cell lung cancer ...

Excellergy is developing medicines that combat allergic responses in three different ways, a multipronged effect the company ...

Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where ...

Among the largest private biotech funding rounds this year, the financing will support global trials of an obesity shot that ...